Slide 1: Q4 2020 Earnings Conference Call
Q4 2020 Earnings Conference Call March 4, 2021 ©2021 ViewRay, Inc. All rights reserved. Exhibit 99.2
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “w
Slide 3: Our Mission: Treat and Prove What Others Can't
Our Mission: Treat and Prove What Others Can’t. >65 patients treated2 More than 3,000 patients with clinically reported outcomes1 ©2021 ViewRay, Inc. All rights reserved. 3
Slide 4: Q4 2020 Financial Results Conference Call
Q4 2020 Financial Results Conference Call 5 MRIdian orders Revenue: $18.5 million, Three units, including one upgrade Used ~$7 million of cash Backlog increased to $241 million ©2021 ViewRay, Inc. All rights reserved. 4
Slide 5: Pipeline Update
Pipeline Update1 Commercial Therapy Adoption Innovation/Product Sub 20-minute treatment times Workflow Automation Enhanced MRI imaging Increased dosing Brain treatment package Remote access Cost reduction Clinical Move from exploratory to confirmatory and definitive data: Phase 1, 2, 3 ©2021 ViewRay
Slide 6: Customers' Definition of Clinical Success
©2021 ViewRay, Inc. All rights reserved. Customers’ Definition of Clinical Success MRIdian 51 MRIdian SMART: Stereotactic MR-guided Adaptive Radiotherapy Among alternatives in the clinical landscape, we have found only MRIdian’s evidence that fits this criteria Ablative Dose Tight Margins No Fiducia
Slide 7: MRIdian Expands the Utility of Radiation Therapy
MRIdian Expands the Utility of Radiation Therapy Soft tissue subject to intra-therapy movement - weighted average utilization: 5% RT is under-utilized in soft tissue tumors ©2021 ViewRay, Inc. All rights reserved.
Slide 8: MRIdian: Expanding Opportunity in Practice
Net new patients:1,2 Establish new programs for patients generally not treated on conventional linacs Patients traveling outside catchment area3 Increase in-network referrals2 MRIdian: Expanding Opportunity in Practice ©2021 ViewRay, Inc. All rights reserved. 8
Slide 9: MRIdian SMART enables program shift to SBRT
MRIdian SMART enables program shift to SBRT % MRIdian patients National SBRT Average2 Customers moving from IMRT to SBRT on MRIdian MRIdian SBRT Mix1 ©2021 ViewRay, Inc. All rights reserved. 9
Slide 10: Patients Treated Annually: 85% CAGR
from 2014-20201 Patients Treated Annually: 85% CAGR ©2021 ViewRay, Inc. All rights reserved.
Slide 11: Focused-Beachhead Patient-Centric Roadmap
Focused-Beachhead Patient-Centric Roadmap Bone #1 #2 #3 #4 Expand utilization of MRIdian SMART Become first line therapy PANCREAS PROSTATE LUNG BRAIN GI GU Thoracic Cranial ©2021 ViewRay, Inc. All rights reserved. 11
Slide 12: Clinical study program by phase
©2021 ViewRay, Inc. All rights reserved. Prospective studies. Larger ‘N’ Confirm signals in key tumor sites Safety and Efficacy endpoints Randomized controlled trials Comparative Safety and efficacy endpoints 60+ investigator-initiated trials Feasibility Explore new indications/expand SMART Reduce f
Slide 13: Where We Are Going – Pancreas
Retrospective data1 (feasibility) Late-stage metastatic3 SMART2 (inoperable/borderline resectable) Medically inoperable4 Exploratory/Phase 1 Confirmatory/Phase 2 Confirmatory/Phase 2 RCT Definitive/Phase 3 RCT Where We Are Going – Pancreas GOAL: Bring MRIdian to ALL pancreatic cancer patients Starte
Slide 14: Delivering Safety and Efficacy Data for MRIdian SMART Adoption
Delivering Safety and Efficacy Data for MRIdian SMART Adoption Today Tomorrow Future Pancreas Cancer Prostate Cancer Metastatic Cancer Phase 3 RCT (SBRT for medically inoperable) 2 Phase 3 MIRAGE RCT (5x MRIdian SMART vs 5x conventional with fiducials) 5 Study Phase: ENROLLING Study Phase: ENROLLING
Slide 15: MRIdian Enables Progression of Therapy
MRIdian Enables Progression of Therapy Improve economic performance & increase TAM Patients pushing, and physicians pulling, for shorter courses of treatment Smart ONE1: Multicenter, single-arm phase 1, single-fraction therapy in both primary tumors and oligomets located in lung, pancreas, liver, ki
Slide 16: Improve economic performance & increase TAM
Improve economic performance & increase TAM New patients generally not treated on conventional linacs2,3 Patients traveling outside catchment area4 Increase in-network referrals3 MRIdian 51 = Top and Bottom Line Impact for Customers + Customers Purchasing Multiple MRIdian Systems Ablative dose Tight
Slide 17: Financial Results Q4 2020
Financial Results Q4 2020 ©2021 ViewRay, Inc. All rights reserved.
Slide 18: Financial Results Q4 and Full Year 2020
Financial Results Q4 and Full Year 2020 In thousands Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 18 ©2021 ViewRay, Inc. All rights reserved.
Slide 19: Question and Answer Session
Question and Answer Session 19 ©2021 ViewRay, Inc. All rights reserved.
Slide 20: Presentation Citations
Presentation Citations Slide 3 Internal and historical company data 12/31/20 MRIdian log data Slide 5 This presentation is intended for investors and analysts only. Some features described herein are not and may never be cleared or approved for sale in all markets. Slide 6 Henke, L., et al. (2018).
Slide 21: Presentation Citations
Presentation Citations Slide 8 “Day One, All-Day Adaptive: Dana-Farber/Brigham and Women's Cancer Center Maximizes Clinical Value of MRIdian,” 7/23/20. Dr. Nagar, Cornell University, October 2020. Dr. Michael Choung, Miami Cancer Institute. “Physician-led Webinar for Investors and Analysts at 2020 A
Slide 22: Presentation Citations
Presentation Citations Slide 13 Rudra S. et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Medicine, 8(5), 2123-2132 SMART: Clinicaltrials.gov - https://clinicaltrials.gov/ct2/show/NCT03621644 University of Zurich, P
Slide 23: Presentation Citations
Presentation Citations Slide 16 1. - Henke, L., et al. (2018). Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 126(3), 519-526; Henke LE, et al. Ster